US Patent Issued to Immedica Pharma US on Oct. 27 for "Ganaxolone for use in treatment of super refractory status epilepticus" (Pennsylvania Inventors)

ALEXANDRIA, Va., Oct. 27 -- United States Patent no. 12,773,412, issued on Oct. 27, was assigned to Immedica Pharma US Inc. (Radnor, Pa.).

"Ganaxolone for use in treatment of super refractory status epilepticus" was invented by Henrikas Vaitkevicius (Radnor, Pa.), Maciej Gasior (Radnor, Pa.) and Joseph Hulihan (Radnor, Pa.).

According to the abstract* released by the U.S. Patent & Trademark Office: "This invention relates to methods for treating super refractory status epilepticus by rapidly weaning the subject in need thereof off an anesthetic agent prior to initiation of administering to the subject in need thereof of ganaxolone at a high infusion dose. The method provides SE suppression and continued suppression of SE."

The patent was...